OncoSTING Overview

  • Founded
  • 2018
  • Status
  • Private
  • Latest Deal Type
  • Early Stage VC
  • Latest Deal Amount
  • $150K
Latest Deal Amount
  • Investors
  • 2

OncoSTING General Information


Developer of therapies designed to cure bladder cancer. The company's therapies work by combining the potency of standard BCG immunotherapy with long-lived delivery of potent STING agonists, enabling doctors to cure bladder cancer with reduced adverse events associated with traditional BCG.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Therapeutic Devices
Primary Office
  • Baltimore, MD
  • United States

OncoSTING Timeline

Financing RoundFinancing Round
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

OncoSTING Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC 02-Jul-2019 $150K 00000 Completed Startup
3. Accelerator/Incubator 28-Jun-2019 Completed Startup
2. Grant 01-Jul-2018 Completed Startup
1. Grant 23-Feb-2018 Completed Startup
To view OncoSTING’s complete valuation and funding history, request access »

OncoSTING Executive Team (4)

Name Title Board Seat Contact Info
Ambaw Bellete President & Business Advisor
Trinity Bivalacqua Ph.D Co-Founder
William Bishai Ph.D Co-Founder
You’re viewing 3 of 4 executive team members. Get the full list »

OncoSTING Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Johns Hopkins University Endowment Limited Partner 000 0000 000000 0
TEDCO Venture Capital Minority 000 0000 000000 0
To view OncoSTING’s complete investors history, request access »